Searching the Resource Information Network

Our searching services are busy right now. Please try again later

  • Register
X
Forgot Password

If you have forgotten your password you can enter your email here and get a temporary password sent to your email.

X

Leaving Community

Are you sure you want to leave this community? Leaving the community will revoke any permissions you have been granted in this community.

No
Yes

Metabolomic Profiling of Left Ventricular Diastolic Dysfunction in Women With or at Risk for HIV Infection: The Women's Interagency HIV Study.

Claudio A Bravo | Simin Hua | Amy Deik | Jason Lazar | David B Hanna | Justin Scott | Jin Choul Chai | Robert C Kaplan | Kathryn Anastos | Octavio A Robles | Clary B Clish | Jorge R Kizer | Qibin Qi
Journal of the American Heart Association | 2020

Background People living with HIV have an increased risk of left ventricular diastolic dysfunction (LVDD) and heart failure. HIV-associated LVDD may reflect both cardiomyocyte and systemic metabolic derangements, but the underlying pathways remain unclear. Methods and Results To explore such pathways, we conducted a pilot study in the Bronx and Brooklyn sites of the WIHS (Women's Interagency HIV Study) who participated in concurrent, but separate, metabolomics and echocardiographic ancillary studies. Liquid chromatography tandem mass spectrometry-based metabolomic profiling was performed on plasma samples from 125 HIV-infected (43 with LVDD) and 35 HIV-uninfected women (9 with LVDD). Partial least squares discriminant analysis identified polar metabolites and lipids in the glycerophospholipid-metabolism and fatty-acid-oxidation pathways associated with LVDD. After multivariable adjustment, LVDD was significantly associated with higher concentrations of diacylglycerol 30:0 (odds ratio [OR], 1.60, 95% CI [1.01-2.55]); triacylglycerols 46:0 (OR 1.60 [1.04-2.48]), 48:0 (OR 1.63 [1.04-2.54]), 48:1 (OR 1.62 [1.01-2.60]), and 50:0 (OR 1.61 [1.02-2.53]); acylcarnitine C7 (OR 1.88 [1.21-2.92]), C9 (OR 1.99 [1.27-3.13]), and C16 (OR 1.80 [1.13-2.87]); as well as lower concentrations of phosphocholine (OR 0.59 [0.38-0.91]). There was no evidence of effect modification of these relationships by HIV status. Conclusions In this pilot study, women with or at risk of HIV with LVDD showed alterations in plasma metabolites in the glycerophospholipid-metabolism and fatty-acid-oxidation pathways. Although these findings require replication, they suggest that improved understanding of metabolic perturbations and their potential modification could offer new approaches to prevent cardiac dysfunction in this high-risk group.

Pubmed ID: 32063116

Research resources used in this publication

None found

Antibodies used in this publication

None found

Associated grants

  • Agency: NIDDK NIH HHS, United States
    Id: P30 DK040561
  • Agency: NHLBI NIH HHS, United States
    Id: R01 HL132794
  • Agency: NICHD NIH HHS, United States
    Id: U01 HD032632
  • Agency: NIAID NIH HHS, United States
    Id: U01 AI031834
  • Agency: NHLBI NIH HHS, United States
    Id: R01 HL140976
  • Agency: NIAID NIH HHS, United States
    Id: U01 AI042590
  • Agency: NHLBI NIH HHS, United States
    Id: U01 HL146204
  • Agency: NIAID NIH HHS, United States
    Id: U01 AI034994
  • Agency: NCATS NIH HHS, United States
    Id: UL1 TR000004
  • Agency: NIAID NIH HHS, United States
    Id: U01 AI035004
  • Agency: NHLBI NIH HHS, United States
    Id: K01 HL137557
  • Agency: NIAID NIH HHS, United States
    Id: U01 AI103390
  • Agency: NIAID NIH HHS, United States
    Id: P30 AI050410
  • Agency: NIAID NIH HHS, United States
    Id: P30 AI027767
  • Agency: NHLBI NIH HHS, United States
    Id: R01 HL095140
  • Agency: NIAID NIH HHS, United States
    Id: U01 AI103401
  • Agency: NHLBI NIH HHS, United States
    Id: K24 HL135413
  • Agency: NHLBI NIH HHS, United States
    Id: R01 HL126543
  • Agency: NHLBI NIH HHS, United States
    Id: R01 HL083760
  • Agency: NIAID NIH HHS, United States
    Id: U01 AI103408
  • Agency: NHLBI NIH HHS, United States
    Id: K01 HL129892
  • Agency: NIAID NIH HHS, United States
    Id: U01 AI034989
  • Agency: NCATS NIH HHS, United States
    Id: UL1 TR000454
  • Agency: NIAID NIH HHS, United States
    Id: U01 AI034993
  • Agency: NIAID NIH HHS, United States
    Id: U01 AI103397
  • Agency: NIA NIH HHS, United States
    Id: R21 AG059505

Publication data is provided by the National Library of Medicine ® and PubMed ®. Data is retrieved from PubMed ® on a weekly schedule. For terms and conditions see the National Library of Medicine Terms and Conditions.

This is a list of tools and resources that we have found mentioned in this publication.


SPSS (tool)

RRID:SCR_002865

Software package used for interactive, or batched, statistical analysis in social science, health sciences and marketing. Software platform offers advanced statistical analysis, a library of machine-learning algorithms, text analysis, open-source extensibility, integration with big data and deployment into applications.Versions that were produced by SPSS Inc. before the IBM acquisition (Versions 18 and earlier) would be given origin or publisher of SPSS Inc. in Chicago.

View all literature mentions

Cytoscape (tool)

RRID:SCR_003032

Software platform for complex network analysis and visualization. Used for visualization of molecular interaction networks and biological pathways and integrating these networks with annotations, gene expression profiles and other state data.

View all literature mentions

Progenesis QI (tool)

RRID:SCR_018923

Software tool as next generation in LC-MS proteomics data analysis software by Nonlinear Dynamics.

View all literature mentions

Thermo Scientific TraceFinder (tool)

RRID:SCR_023045

Software set of acquisition and data processing tools. LC/MS analytical software. Enables control of multi-channel LC, single quadrupole, triple quadrupole and high-resolution LC-MS systems, as well as IC and GC systems.

View all literature mentions